Literature DB >> 33206858

SURVIVAL OF PATIENTS WITH COLORECTAL CANCER IN A CANCER CENTER.

Samuel Aguiar Junior1, Max Moura de Oliveira2, Diego Rodrigues Mendonça E Silva2, Celso Abdon Lopes de Mello3, Vinicius Fernando Calsavara2, Maria Paula Curado2.   

Abstract

BACKGROUND: Hospital-based studies recently have shown increases in colorectal cancer survival, and better survival for women, young people, and patients diagnosed at an early disease stage.
OBJECTIVE: To describe the overall survival and analyze the prognostic factors of patients treated for colorectal cancer at an oncology center.
METHODS: The analysis included patients diagnosed with colon and rectal adenocarcinoma between 2000 and 2013 and identified in the Hospital Cancer Registry at A.C.Camargo Cancer Center. Overall 5-year survival was estimated using the Kaplan-Meier method, and prognostic factors were evaluated in a Cox regression model. Hazard ratios (HR) are reported with 95% confidence intervals (CI).
RESULTS: Of 2,279 colorectal cancer cases analyzed, 58.4% were in the colon. The 5-year overall survival rate for colorectal cancer patients was 63.5% (65.6% and 60.6% for colonic and rectal malignancies, respectively). The risk of death was elevated for patients in the 50-74-year (HR=1.24, 95%CI =1.02-1.51) and ≥75-year (HR=3.02, 95%CI =2.42-3.78) age groups, for patients with rectal cancer (HR=1.37, 95%CI =1.11-1.69) and for those whose treatment was started >60 days after diagnosis (HR=1.22, 95%CI =1.04-1.43). The risk decreased for patients diagnosed in recent time periods (2005-2009 HR=0.76, 95%CI =0.63-0.91; 2010-2013 HR=0.69, 95%CI =0.57-0.83).
CONCLUSION: Better survival of patients with colorectal cancer improves with early stage and started treatment within 60 days of diagnosis. Age over 70 years old was an independent factor predictive of a poor prognosis. The overall survival increased to all patients treated in the period 2000-2004 to 2010-2013.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33206858     DOI: 10.1590/S0004-2803.202000000-32

Source DB:  PubMed          Journal:  Arq Gastroenterol        ISSN: 0004-2803


  13 in total

1.  Sevoflurane Suppresses the Proliferation, Migration and Invasion of Colorectal Cancer Through Regulating Circ_0000423/miR-525-5p/SGPP1 Network.

Authors:  Xiaofang Kang; Xiaocong Li; Yanli Li
Journal:  Cell Mol Bioeng       Date:  2022-01-22       Impact factor: 2.321

2.  Tobacco-related neoplasms: survival analysis and risk of death of population data from Florianópolis, SC.

Authors:  Ione Jayce Ceola Schneider; Tauana Prestes Schmidt; Vanessa Pereira Correa; Ana Maria Martins Dos Santos; Bruna Vanti da Rocha; Leandro Pereira Garcia; Roger Flores Ceccon
Journal:  Rev Saude Publica       Date:  2022-04-08       Impact factor: 2.106

3.  Epigallocatechin-3-gallate inhibits the formation of neutrophil extracellular traps and suppresses the migration and invasion of colon cancer cells by regulating STAT3/CXCL8 pathway.

Authors:  Zhuoxian Zhang; Qiuli Zhu; Siya Wang; Chao Shi
Journal:  Mol Cell Biochem       Date:  2022-09-16       Impact factor: 3.842

4.  Analysis of miR-143, miR-1, miR-210 and let-7e Expression in Colorectal Cancer in Relation to Histopathological Features.

Authors:  Hanna Romanowicz; Piotr Hogendorf; Alicja Majos; Adam Durczyński; Dariusz Wojtasik; Beata Smolarz
Journal:  Genes (Basel)       Date:  2022-05-13       Impact factor: 4.141

5.  Predictors of Quality of Life Six Years after Curative Colorectal Cancer Surgery: Results of the Prospective Multicenter Study.

Authors:  Gintare Valeikaite-Tauginiene; Agne Kraujelyte; Eligijus Poskus; Valdemaras Jotautas; Zilvinas Saladzinskas; Algimantas Tamelis; Paulius Lizdenis; Audrius Dulskas; Narimantas Evaldas Samalavicius; Kęstutis Strupas; Tomas Poškus
Journal:  Medicina (Kaunas)       Date:  2022-03-26       Impact factor: 2.948

6.  PIK3C3 Inhibition Promotes Sensitivity to Colon Cancer Therapy by Inhibiting Cancer Stem Cells.

Authors:  Balawant Kumar; Rizwan Ahmad; Swagat Sharma; Saiprasad Gowrikumar; Mark Primeaux; Sandeep Rana; Amarnath Natarajan; David Oupicky; Corey R Hopkins; Punita Dhawan; Amar B Singh
Journal:  Cancers (Basel)       Date:  2021-04-30       Impact factor: 6.639

7.  The Effect of miR-145-5p, DANCR and NRAS Expression Levels on the Survival Rate of Colorectal Cancer Patients.

Authors:  Fatemeh Bahreini; Masoud Saidijam; Saeid Afshar; Zahra Mousivand; Rezvan Najafi
Journal:  Asian Pac J Cancer Prev       Date:  2021-12-01

Review 8.  The Interaction Between N6-Methyladenosine Modification and Non-Coding RNAs in Gastrointestinal Tract Cancers.

Authors:  Lin Yao; Chang-Feng Man; Rong He; Lian He; Jia-Bin Huang; Shou-Yan Xiang; Zhe Dai; Xiao-Yan Wang; Yu Fan
Journal:  Front Oncol       Date:  2022-01-07       Impact factor: 6.244

9.  Comparison of Prognosis and Lymph Node Metastasis in T1-Stage Colonic and Rectal Carcinoma: A Retrospective Study.

Authors:  Jun Deng; Shifa Zhou; Zhiwen Wang; Genbo Huang; Jingjun Zeng; Xiujiang Li
Journal:  Int J Gen Med       Date:  2022-04-05

10.  Significance of long non-coding RNA IFNG-AS1 in the progression and clinical prognosis in colon adenocarcinoma.

Authors:  Zhaoshun Wang; Zhongzheng Cao; Zhen Wang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.